SCHEMBL2997249

SCHEMBL2997249

CCCC[Sn](CCCC)(CCCC)c1cc2c(Cl)c(F)cnc2n1S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 5/20 0.34
LMNA P02545 3/20 0.34
AGTR1 P30556 1/20 0.34
CCKAR P32238 1/20 0.34
MAPT P10636 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TSHR P16473 3/20 0.32
TP53 P04637 3/20 0.32
KDM4E B2RXH2 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ALDH1A1 P00352 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
PPARG P37231 1/20 0.31
PPARD Q03181 1/20 0.31
NPC1 O15118 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2982552 0.83 PTGDR2 (0.40) PTGDR2LMNAAGTR1CCKARTSHR
SCHEMBL29772861 0.83 PTGDR2 (0.40) PTGDR2LMNAAGTR1CCKARTSHR
SCHEMBL2988406 0.81 LMNA (0.36) PTGDR2LMNAAGTR1MAPTTSHR
SCHEMBL1749189 0.78 PTGDR2 (0.37) PTGDR2LMNACCKARMAPTCYP3A4
SCHEMBL2994721 0.77 PTGDR2 (0.39) PTGDR2LMNAAGTR1CCKARMAPT
SCHEMBL3093501 0.74 L3MBTL1 (0.48) PTGDR2LMNAAGTR1CCKARMAPT
SCHEMBL1748728 0.69 L3MBTL1 (0.49) MAPTKDM4EL3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL29131766 0.69 RAPGEF4 (0.40) LMNACYP2C9CYP2C19TSHRKDM4E
SCHEMBL34475350 0.69 PIK3CD (0.36) PTGDR2LMNAMAPTSMN1; SMN2GAA
SCHEMBL20536581 0.68 ABL1 (0.40) PTGDR2LMNAAGTR1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799691-B1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-12-21 EP disclosed
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 EP disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 PTGDR2 1281/4885LMNA 3052/4885AGTR1 924/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 PTGDR2 1281/4885LMNA 3052/4885AGTR1 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.